title: The antepartum glucose values that predict neonatal macrosomia differ from those that predict postpartum prediabetes or diabetes: implications for the diagnostic criteria for gestational diabetes.
abstract: OBJECTIVE
  The diagnosis of gestational diabetes mellitus on oral glucose tolerance test (OGTT) is used to identify risk of both neonatal large-for-gestational-age (LGA) and maternal postpartum prediabetes/diabetes. An assumption inherent in this practice, however, is that the glucose values that define gestational diabetes mellitus on the OGTT relate to both of these outcomes in the same way. Thus, to test this assumption, we sought to evaluate the predictive capacity of each glucose value on antepartum OGTT in relation to LGA and postpartum prediabetes/diabetes.
  
  
  METHODS
  A total of 412 women representing the full spectrum of antepartum glucose tolerance underwent 3-h OGTT in pregnancy, assessment of obstetrical outcome at delivery, and 2-h OGTT at 3 months postpartum.
  
  
  RESULTS
  Of the four glucose values (fasting, 1h, 2 h, 3 h) on antepartum OGTT, only the fasting measure was a significant predictor of LGA [odds ratio (OR) 2.00 per mmol/liter, 95% confidence interval (CI) 1.20-3.34] (P = 0.0076). In contrast, all three postload glucose values were significant predictors of postpartum prediabetes/diabetes (1 h glucose: OR 1.37, 95% CI 1.17-1.61, P < 0.0001; 2 h glucose: OR 1.55, 95% CI 1.32-1.83, P < 0.0001; 3 h glucose: OR 1.30, 95% CI 1.10-1.53, P = 0.002), whereas fasting glucose was not. Furthermore, whereas fasting glucose had the highest area under the receiver operating characteristic curve for predicting LGA (0.62), the 1- and 2-h glucose measures had the highest area under the receiver operating characteristic curve values for postpartum prediabetes/diabetes (0.68 and 0.72, respectively).
  
  
  CONCLUSIONS
  On antepartum OGTT, the fasting glucose value best predicts LGA risk, whereas postload glucose values predict postpartum prediabetes/diabetes. These relationships may have implications for the glycemic thresholds that define obstetrical and metabolic risk.
authors.affiliation: Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada M5T3L9. rretnakaran@mtsinai.on.ca
authors.forename: Ravi
authors.initials: R
authors.lastname: Retnakaran
authors.forename: Ying
authors.initials: Y
authors.lastname: Qi
authors.forename: Mathew
authors.initials: M
authors.lastname: Sermer
authors.forename: Philip W
authors.initials: PW
authors.lastname: Connelly
authors.forename: Anthony J G
authors.initials: AJ
authors.lastname: Hanley
authors.forename: Bernard
authors.initials: B
authors.lastname: Zinman
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis*; D003920:Diabetes Mellitus / Q000175:diagnosis*; D016640:Diabetes, Gestational / Q000175:diagnosis*; D005260:Female; D005320:Fetal Macrosomia / Q000175:diagnosis*; D005951:Glucose Tolerance Test; D006801:Humans; D007231:Infant, Newborn; D011236:Prediabetic State / Q000175:diagnosis*; D011247:Pregnancy; D011644:Puerperal Disorders / Q000175:diagnosis*
chemical_list: D001786:Blood Glucose